Oryx Biotech, a subsidiary of Oryx Biotech Holdings based in China, will finance the amount in building up its plasma fractionation plant at Summit Technopolis at Bangabandhu Hi-Tech Park in Gazipur. To this end, Oryx Biotech on Tuesday inked a tripartite agreement with Summit Technopolis and Bangladesh Hi-Tech Park Authority (BHTPA) in Dhaka. The plant will have the capacity of processing 1,200 tonnes of plasma annually at 20 plasma collection centres all over the country. Aziz Khan said, “We are pleased to activate the nation's first and largest biotech investment of about $300 million on 25 acres of land and building provided by Summit Technopolis at Gazipur. Managing Director of Oryx Biotech David Bo David Bo and his colleagues from China took part in the program virtually.

Source: Dhaka Tribune August 11, 2020 15:00 UTC